You've spent ten weeks rebuilding the machinery. NAD+ levels are restored, mitochondrial density is up, the electron transport chain is moving cleanly. Here's what most people get wrong about what happens next: they treat the protocol like an antibiotic course — finish it, walk away, expect the result to hold. It won't. Cellular energy is a flow, not a deposit. The mitochondria you just rebuilt are already aging. The NAD+ you just restored is being burned by PARP, CD38, and the daily oxidative load of being alive. Maintenance isn't optional. It's the protocol.
The good news: the maintenance load is roughly 10–20% of the intervention load. You're not running the full reset stack forever. You're running a small, persistent floor of mitochondrial support, layered with annual telomere pulses and quarterly mitochondrial-biogenesis cycles. The compounds you keep, the compounds you pulse, and the compounds you retire each follow different logic — and that logic is what this chapter locks in.
What's actually decaying
Three clocks run against you the moment Phase 2 ends.
Clock one — NAD+ drainage. NNMT enzyme activity rises with age and with metabolic stress. Every methylation reaction, every PARP-mediated DNA repair event, every CD38-driven immune signal burns NAD+. Without ongoing input, the salvage pathway loses ground. The practitioner corpus is explicit: NAD+/NADH ratio is a leading indicator of cellular energy efficiency, and it falls quietly. You will not feel the slide for 6–9 months — by then you've lost meaningful ground.
Clock two — mitochondrial membrane integrity. Cardiolipin, the signature phospholipid of the inner mitochondrial membrane, oxidizes continuously. As cardiolipin oxidizes, the electron transport chain supercomplexes destabilize, ΔΨm (membrane potential) drops, and ATP output falls. This is the structural decay SS-31 was engineered to prevent — and it resumes the day you stop supporting the membrane.
Clock three — telomere attrition and AMPK desensitization. Each cell division shortens telomeres. AMPK — the master energy sensor MOTS-c activates — desensitizes under continuous stimulation. This is why MOTS-c cannot be run indefinitely the way BPC-157 can. The receptor requires rest to remain responsive. Continuous dosing flips the dose-response curve from beneficial to harmful.
Maintenance protocol architecture maps directly onto these three clocks: a daily floor for NAD+ and membrane support, a quarterly pulse for mitochondrial biogenesis, an annual or biannual pulse for telomere and pineal-axis reset.
The maintenance stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| 5-Amino-1MQ | 50–100 mg/day | Oral | Daily, continuous | Expert | Run forever. Blocks NNMT, preserves NAD+ pool. No cycling required per practitioner consensus. |
| Methylene Blue | 0.5–1 mg | Oral, morning | 5 days on / 2 days off, long-term | Expert | Pharmaceutical-grade dose only. Higher doses flip dose-response. Stabilizes electron transport. |
| NAD+ (subcutaneous) | 50–100 mg | SubQ | 1–2x weekly maintenance | Expert | Maintenance pulse, not loading. Bypasses oral absorption ceiling. |
| MOTS-c | 5–10 mg/week total | SubQ | 2–3x weekly, 12 weeks on / 4 weeks off | Expert | Mandatory cycling. Continuous use desensitizes AMPK. |
| Epitalon | 5–10 mg/day × 10–20 days | SubQ | 2–3 cycles per year (every 4–6 months) | Expert / Experimental | Telomerase activation pulse. 15-year human data at standard doses. Short cycles preserve safety profile. |
| SS-31 (Elamipretide) | 0.01–0.25 mg/kg | SubQ | Practitioner-directed; conservative maintenance | Clinical (for primary mito myopathy) / Experimental (for healthy maintenance) | Membrane-targeted. Higher doses (4–40 mg) reserved for diagnosed mitochondrial disease. |
| NMN (optional adjunct) | 500 mcg – 1 mg/day × 10–20 days | SubQ | Quarterly pulse | Expert | Pairs with 5-Amino-1MQ — NMN raises supply, 5-Amino-1MQ reduces waste. Net positive NAD+ balance. |
| B-Complex | Standard dose | Oral | Daily with breakfast | Expert | Fuels the folate–methionine cycle MOTS-c optimizes. B1, B2, B6 support NAD+ salvage. |
A note on SS-31 maintenance: the practitioner corpus is conservative here. Clinical trial dosing for diagnosed mitochondrial myopathy runs 40 mg/day for 24 weeks. For healthy maintenance in a post-protocol researcher, the substrate supports the 0.01–0.25 mg/kg range under practitioner guidance. [Practitioner corpus thin on optimal frequency for healthy-maintenance SS-31 — track and report.]
The annual rhythm
Maintenance is calendar-driven, not symptom-driven. Build the year before the year builds you.
- Months 1, 2, 3 — Daily floor: 5-Amino-1MQ + Methylene Blue + B-Complex. MOTS-c cycle one (12 weeks on).
- Month 4 — MOTS-c off-cycle (4 weeks rest). Daily floor continues. NMN pulse here.
- Month 4 — Epitalon cycle one — 5–10 mg/day × 10–20 days. Schedule deliberately in the MOTS-c off-window so the AMPK and telomerase axes don't compete for attention.
- Months 5, 6, 7 — MOTS-c cycle two. NAD+ SubQ 1–2x weekly continues.
- Month 8 — MOTS-c off-cycle. Epitalon cycle two.
- Months 9, 10, 11 — MOTS-c cycle three (optional, depends on labs). Some practitioners run two MOTS-c cycles per year, others run three. Lactate/pyruvate ratio and NAD+/NADH ratio tell you which.
- Month 12 — Reassessment window. Pull full lab panel. Optional Epitalon cycle three for the 3x/year schedule.
What you should feel
- Months 1–3 — energy floor holds. The deep-fatigue ceiling you broke in Phase 2 doesn't return.
- Month 4 (first Epitalon pulse) — practitioner reports describe normalized circadian rhythms, restored melatonin production, deeper sleep onset within 7–10 days of pulse start.
- Months 6–9 — sustained metabolic flexibility. Fasting tolerance improves. Recovery from training shortens.
- Month 12 — labs confirm the holding pattern. NAD+/NADH ratio stable or improving. Lactate/pyruvate ratio below baseline.
What's NOT happening yet
- You are not "done." Maintenance is the protocol. There's no graduation.
- You will not feel acute results from maintenance dosing. Daily 5-Amino-1MQ doesn't feel like the Phase 2 stack felt. Absence of decline is the win — and absence is invisible until you stop and watch it return.
- MOTS-c off-weeks are not optional. Skipping the 4-week rest does not give you more benefit. It gives you AMPK desensitization, paradoxical fatigue, and a flatter response next cycle.
- Epitalon does not "build up" with continuous use. The 10–20 day pulse architecture exists because pulsatile exposure mimics the pineal axis's own rhythm. Running it daily for 90 days does not produce 9x the result.
- Higher Methylene Blue is not better. The 10–15 mg doses circulated online flip the curve. 0.5–1 mg is the pharmaceutical-grade ceiling for daily neuronal/mitochondrial support.
- Maintenance does not erase aging. It slows the slope. Telomeres still shorten — just slower. Mitochondria still senesce — just slower. The premise is decade-scale, not month-scale.
Research describes this rhythm. Track your NAD+/NADH ratio, your lactate/pyruvate ratio, and your subjective energy floor. Adjust.